Dear IBRI stakeholders,
I am pleased to share with you that the Indiana Biosciences Research Institute (IBRI) has made great strides in the past year. We have worked diligently to implement our updated strategy and we are eager to share our progress with you.
Discovery with purpose - accelerated
Throughout this report you will see examples of how we are building and integrating new capabilities to enable our ambitious strategy that is focused on key longer-term objectives:
We have expanded and diversified our scientific program. For example, the amount of funding in our external grant proposals increased by 44 percent, and the number of proposals are now more evenly distributed among our lead investigators. This represents a true expansion of research scope and capabilities in concert with our new strategy. You’ll see more detail about our funding progress here.
We have celebrated our first full year of scientific and administrative operations in Innovation Building 1 within the 16 Tech Innovation District. The new, expanded facility has allowed us to increase by 50 percent the number of life sciences startups that call our space home. You can learn about two of them – Helix BioStructures and Adipo Therapeutics.
The time is now
We must build on these achievements. As we look to 2022 and beyond, there are tremendous opportunities ahead. I anticipate that the IBRI will continue to be seen as a visible and influential member of the local community. I believe our expanded footprint will attract top talent to the life sciences ecosystem and that our scientific progress will lead to translational outcomes and increased funding potential. I envision growing our philanthropic network and creating new partner company opportunities.
All of this and more is possible with you. I appreciate your support, partnership and commitment to our collective success as we move forward on this exciting journey.
Alan Palkowitz, PhD
President & CEO
Indiana Biosciences Research Institute